Huayuan Regenerative Medicine Completes Tens of Millions RMB Pre-A++ Financing to Advance Bioartificial Organs into Clinical Stage

In June 2023, Shenzhen Huayuan Regenerative Medicine completed a Pre-A++ financing round of tens of millions of yuan, led by Deyi Capital, with participation from Westlake Photonics, Kangyu Capital, Top Capital, Xiamen High-Tech Investment, and Kexi Capital. Mingxi Capital continued to serve as the financial advisor for this round. This successful fundraising follows the Pre-A+ round led by Efung Capital last December, providing financial support to advance the company’s products into the clinical stage.

In 2023, the bio-artificial organ industry experienced rapid development, with major pharmaceutical companies such as Novo Nordisk, Eli Lilly, United Therapeutics, and Vertex increasingly establishing a presence in this sector. AR (Huayuan Regenerative Medicine), founded in 2018, has established GMP-compliant facilities for bio-artificial organ devices and cell production in Shenzhen, advancing the gradual transfer of its artificial kidney and pancreas products to commercial manufacturing. The company expects to submit Investigational New Drug (IND) applications in batches next year, with some products having completed Investigator-Initiated Trials (IIT). This round of financing will accelerate the commercialization process of the company’s products.

Ms. Li Jun, Co-founder of AR (Huayuan Regenerative Medicine), expressed her sincere gratitude to Deyi Capital, Westlake Photonics, HWealth Capital, TOP CAPITAL, Xiamen High-Tech Investment, and Ke Xi Capital for their recognition of AR’s endeavors in the field of bio-artificial organs. Deyi Capital focuses on VC/PE investments in healthcare, next-generation information technology, and other sectors, having invested in numerous outstanding companies in innovative healthcare, such as Allist Pharmaceutical (688266.SH), Zai Lab (688578.SH), Yifang Biopharma (688382.SH), Yuanli Life, Yingli Pharmaceuticals, Zhimeng Pharma, Weilizhibo, and Aoquan Biology. Westlake Photonics is an investment platform under the Westlake Education Foundation, the sponsor of Westlake University. Leveraging the university’s strengths in key disciplines, it focuses on frontier technology projects that contribute to the sustainable development of humanity and the environment. HWealth Capital, TOP CAPITAL, Xiamen High-Tech Investment, and Ke Xi Capital also possess extensive investment experience and industrial resources in the fields of medical devices and regenerative medicine. The participation of these professional institutions, together with existing shareholders such as Sequoia China and Efung Capital, will provide critical expertise and resources to facilitate the commercial translation of AR’s products and their expansion into international markets.